POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF)
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare bone marrow cancer: drug duo targets spleen swelling and fatigue
Disease control Recruiting nowThis phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for adults with myelofibrosis, a rare bone marrow cancer. The study enrolls 460 people who have not taken JAK inhibitors before. The main goals are to shrink th…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 08:03 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 07:59 UTC